Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies.

Mariotti J, Spina F, Carniti C, Anselmi G, Lucini D, Vendramin A, Pregliasco F, Corradini P.

Eur J Haematol. 2012 Aug;89(2):111-9. doi: 10.1111/j.1600-0609.2012.01793.x. Epub 2012 May 31.

PMID:
22540245
2.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K.

Haematologica. 2011 Feb;96(2):307-14. doi: 10.3324/haematol.2010.032664. Epub 2010 Oct 22.

3.

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.

Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT.

Int J Infect Dis. 2012 Aug;16(8):e621-7. doi: 10.1016/j.ijid.2012.04.010. Epub 2012 Jun 15.

4.

Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.

Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.

Vaccine. 2012 Jul 13;30(33):5009-18. doi: 10.1016/j.vaccine.2012.05.016. Epub 2012 May 30.

PMID:
22658967
5.

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.

Herrera MT, Gonzalez Y, Juárez E, Hernández-Sánchez F, Carranza C, Sarabia C, Guzman-Beltran S, Manjarrez ME, Muñoz-Torrico M, Garcia-Garcia L, Sada E, Torres M.

BMC Infect Dis. 2013 Nov 15;13:544. doi: 10.1186/1471-2334-13-544.

6.

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.

Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K.

Biol Blood Marrow Transplant. 2011 May;17(5):632-9. doi: 10.1016/j.bbmt.2010.08.002. Epub 2010 Aug 11.

7.

Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.

Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.

Vaccine. 2012 Nov 6;30(48):6864-70. doi: 10.1016/j.vaccine.2012.09.005. Epub 2012 Sep 16.

PMID:
22989690
8.

Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.

Iorio AM, Bistoni O, Galdiero M, Lepri E, Camilloni B, Russano AM, Neri M, Basileo M, Spinozzi F.

Vaccine. 2012 Feb 21;30(9):1617-23. doi: 10.1016/j.vaccine.2011.12.107. Epub 2012 Jan 13.

PMID:
22245606
9.

Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.

Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C.

Vaccine. 2012 Feb 1;30(6):1108-14. doi: 10.1016/j.vaccine.2011.12.023. Epub 2011 Dec 15.

PMID:
22178515
10.

Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant.

Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, Fortuno ES 3rd, Xu W, Shi L, Kukreti V, Crump M, Kuruvilla J.

Leuk Lymphoma. 2013 Jul;54(7):1387-95. doi: 10.3109/10428194.2012.742524. Epub 2013 Jan 8.

PMID:
23240909
11.

Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.

Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B.

Vaccine. 2012 Dec 14;30(52):7522-8. doi: 10.1016/j.vaccine.2012.10.047. Epub 2012 Oct 25.

PMID:
23103195
12.

Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.

Dhédin N, Krivine A, Le Corre N, Mallet A, Lioure B, Bay JO, Rubio MT, Agape P, Thiébaut A, Le Goff J, Autran B, Ribaud P.

Vaccine. 2014 Jan 23;32(5):585-91. doi: 10.1016/j.vaccine.2013.11.073. Epub 2013 Dec 12.

PMID:
24333120
13.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
14.

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.

Cullen G, Bader C, Korzenik JR, Sands BE.

Gut. 2012 Mar;61(3):385-91. doi: 10.1136/gutjnl-2011-300256. Epub 2011 Jul 13.

PMID:
21757451
15.

Vaccination against influenza in patients with systemic sclerosis.

Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, Braun Y, Anouk M, Kaufman I, Paran D, Caspi D, Elkayam O.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S7-11. Epub 2012 May 29.

PMID:
22409886
16.

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Roll D, Ammer J, Holler B, Salzberger B, Schweiger B, Jilg W, Andreesen R, Edinger M, Wolff D, Holler E.

Infection. 2012 Apr;40(2):153-61. doi: 10.1007/s15010-011-0206-5. Epub 2011 Oct 29.

PMID:
22038110
17.

Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.

Salles MJ, Sens YA, Malafronte P, Souza JF, Vilas Boas LS, Machado CM.

Transpl Infect Dis. 2012 Dec;14(6):564-74. doi: 10.1111/j.1399-3062.2012.00769.x. Epub 2012 Aug 13.

PMID:
22882692
18.

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.

Arthritis Rheum. 2010 Jan;62(1):75-81. doi: 10.1002/art.25033.

19.

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.

Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.

Vaccine. 2011 Feb 17;29(9):1777-82. doi: 10.1016/j.vaccine.2010.12.113. Epub 2011 Jan 7.

PMID:
21216315
20.

Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.

Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D.

J Infect Dis. 2012 Mar 1;205(5):733-44. doi: 10.1093/infdis/jir641.

Items per page

Supplemental Content

Write to the Help Desk